The present invention includes an immunogenic protein, constructs, vectors, and methods of making, comprising at least 90% amino acid identity to at least one antigenic peptide selected from: a coronavirus Receptor Binding Domain (RBD), coronavirus a Receptor Binding Motif (RBM) of a coronavirus spike protein, a coronavirus spike protein N-terminus, a nucleocapsid protein, one or more T cell epitopes from a coronavirus spike protein, or one or more T cell epitopes from a coronavirus nucleocapsid protein, or combination thereof. In one example, the at least one antigenic peptide is positioned at, at least one of, the N-terminus, the C-terminus, or in a loop region of the carrier protein or peptide tag.

In the various aspects and embodiments, this disclosure provides messenger RNA (mRNA) constructs for therapeutic delivery, as well as methods for making such mRNA constructs and pharmaceutical compositions comprising the same (including mRNA vaccine compositions). In still other aspects, the invention provides methods for treating patients by expression of therapeutic proteins, including for preventing or reducing probability of infection by, or illness involving, a virus. Exemplary viruses include coronaviruses (such as SARS-CoV-2 and variants therefore) and influenza viruses, among others.

A pDNA-based vaccine against SARS-CoV-2 and methods for preventing or treating COVID-19 using it.

The present invention relates to an immunogenic composition against virus infection, especially to an immunogenic composition having peptides that are capable of binding to major histocompatibility complex (MHC) molecules and inducing a broad-spectrum immunity against coronavirus.

A cell line of Accession No. NITE P-03458. A producing method of a cell line includes: a transfection step of transfecting a vector into a cell, where the vector includes a nucleic acid sequence encoding a nonstructural protein of a coronavirus, a reporter protein including a drug-resistant protein, and a structural protein of the coronavirus; and a selection step of performing selection on the cell obtained in the transfection step using a drug.

The present invention provides antibodies that neutralize MERS-CoV and methods of use thereof. The invented antibody is used to treat MERS-CoV infections and symptoms thereof.

The present disclosure provides a system for the expression of target protein in conjunction with enhancer protein. The enhancer protein may be a viral protein that blocks nucleocytoplasmic transport. Also provided are polynucleotides, vectors, and cells comprising target protein and enhancer protein nucleic acid sequences.

The present invention provides a SARS-CoV-2 chimeric VLP vaccine composition and an expressing vector and use thereof. The chimeric SARS-CoV-2 VLP comprises a VLP skeleton formed by the M1 protein and the M2 protein of influenza virus, and the chimeric spike protein of SARS-CoV-2, expressed on the surface of the VLP skeleton, the transmembrane domain of which is replaced by the transmembrane domain of a HA of influenza virus. The present invention also provides a recombinant vector expressing the chimeric SARS-CoV-2 VLP, and the use of the chimeric SARS-CoV-2 VLP for eliciting an immune response against SARS-CoV-2 variants.

Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.

In one embodiment, the present specification discloses a modified spike (S) protein comprising of SEQ ID NO: 2, the modified spike protein encoded by a gene sequence of SEQ ID NO: 1, and methods of using the modified spike protein as disclosed herein.